PMID- 34794793
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211130
IS  - 2531-1387 (Electronic)
IS  - 2531-1379 (Print)
IS  - 2531-1379 (Linking)
VI  - 43 Suppl 2
IP  - Suppl 2
DP  - 2021 Nov
TI  - Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on 
      genetically modified cells. I: Structuring centers for the multidisciplinary 
      clinical administration and management of CAR-T cell therapy patients.
PG  - S3-S12
LID - S2531-1379(21)00135-8 [pii]
LID - 10.1016/j.htct.2021.09.001 [doi]
AB  - Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological 
      treatment which has demonstrated impressive response in refractory or relapsed 
      diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but 
      is also associated with unique and potentially life-threatening toxicities. The 
      most common adverse events (AEs) include cytokine release syndrome (CRS), 
      neurological toxicities, such as the immune effector cell-associated 
      neurotoxicity syndrome (ICANS), cytopenias, infections, and 
      hypogammaglobulinemia. These may be severe and require admission of the patient 
      to an intensive care unit. However, these AEs are manageable when recognized 
      early and treated by a duly trained team. The objective of this article is to 
      report a consensus compiled by specialists in the fields of oncohematology, bone 
      marrow transplantation, and cellular therapy describing recommendations on the 
      Clinical Centers preparation, training of teams that will use CAR-T cells, and 
      leading clinical questions as to their use and the management of potential 
      complications.
CI  - Copyright (c) 2021 Associacao Brasileira de Hematologia, Hemoterapia e Terapia 
      Celular. Published by Elsevier Espana, S.L.U. All rights reserved.
FAU - Cle, Diego V
AU  - Cle DV
AD  - Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo (FMRP-USP), 
      Ribeirao Preto, SP, Brazil. Electronic address: diegocle@yahoo.com.
FAU - Hirayama, Alexandre V
AU  - Hirayama AV
AD  - Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
FAU - Alencar, Alvaro J
AU  - Alencar AJ
AD  - Sylvester Comprehensive Cancer Center, University of Miami Miller School of 
      Medicine, Miami, FL, USA.
FAU - Costa, Luciano J
AU  - Costa LJ
AD  - O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, 
      Birmingham, AL, USA.
FAU - Feliciano, Joao V P
AU  - Feliciano JVP
AD  - Hospital de Base, Faculdade de Medicina de Rio Preto (HB FAMERP), Sao Jose do Rio 
      Preto, SP, Brazil.
FAU - Mattos, Ederson R
AU  - Mattos ER
AD  - Fundacao Amaral Carvalho, Jau, SP, Brazil.
FAU - Cordeiro, Ana C
AU  - Cordeiro AC
AD  - A.C. Camargo Cancer Center, Sao Paulo, SP, Brazil.
FAU - Salvino, Marco Aurelio
AU  - Salvino MA
AD  - Hospital Universitario Prof. Edgard Santos, Salvador, BA, Brazil.
FAU - Barros, George M Navarro
AU  - Barros GMN
AD  - Hospital do Cancer de Barretos, SP, Brazil.
FAU - de Lima, Marcos
AU  - de Lima M
AD  - Ohio State University, Columbus, OH, USA.
FAU - Scheinberg, Phillip
AU  - Scheinberg P
AD  - Hospital A Beneficencia Portuguesa, Sao Paulo, Brazil.
FAU - Guerino-Cunha, Renato L
AU  - Guerino-Cunha RL
AD  - Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo (FMRP-USP), 
      Ribeirao Preto, SP, Brazil.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Hematol Transfus Cell Ther
JT  - Hematology, transfusion and cell therapy
JID - 101725732
PMC - PMC8606713
OTO - NOTNLM
OT  - CAR-T cells
OT  - Cellular therapy
OT  - Center structuring
OT  - Complication management
OT  - Cytokine release syndrome
OT  - Neurotoxicity
COIS- Conflicts of interest The authors declare no conflicts of interest.
EDAT- 2021/11/20 06:00
MHDA- 2021/11/20 06:01
PMCR- 2021/11/16
CRDT- 2021/11/19 05:44
PHST- 2021/09/06 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2021/11/19 05:44 [entrez]
PHST- 2021/11/20 06:00 [pubmed]
PHST- 2021/11/20 06:01 [medline]
PHST- 2021/11/16 00:00 [pmc-release]
AID - S2531-1379(21)00135-8 [pii]
AID - 10.1016/j.htct.2021.09.001 [doi]
PST - ppublish
SO  - Hematol Transfus Cell Ther. 2021 Nov;43 Suppl 2(Suppl 2):S3-S12. doi: 
      10.1016/j.htct.2021.09.001.